Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the present invention relates to bicyclic sulfur containing heteroaryls. More particularly, the invention is concerned with substituted thieno[2,3-b]pyrrolidin- 5-one derivatives, a process for their manufacture and pharmaceutical preparations containing them. This invention is further directed to intermediates useful in the preparation of the foregoing compounds and to processes for the preparation of such compounds.
• the novel thienopyrrolidinones can inhibit or modulate the production of tumour necrosis factor (TNF- ⁇ ) from cells.
• TNF- ⁇ tumour necrosis factor
• Compounds of the invention are also able to inhibit the proliferation of cells.
• These compounds and their pharmaceutically acceptable salts are useful as anti- inflammatory agents, particularly useful in the treatment of rheumatoid arthritis, neuro- degenerative diseases such as Alzheimer's, cardiovascular diseases and in cancer therapy.
• the invention is also directed to pharmaceutical compositions containing such compounds, and to methods for the treatment and/or control of the mentioned diseases.
• the invention concerns thienopyrrolidinones of the general formula
• R represents a 5- or 6-membered monocyclic aromatic ring containing one or more hetero atoms independently selected from N, S and O, the remaining being carbon, and which ring may be benz-fused and which monocyclic or benz-fused aromatic ring is optionally substituted independently with one or more groups selected from lower alkyl, lower alkoxy, optionally substituted aryl, optionally substituted aryl- lower alkyl, optionally substituted aryl-lowe alkoxy, halogen, haloalkyl, nitro, hydroxy, cyano, -C(O)R 7 , -(CH 2 ) n CO 2 R 8 or -(CH 2 ) n CONR 7 R 8 , wherein R 7 represents hydrogen, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclyl, or lower alkyl optionally mono substituted by cycloalkyl, optionally substituted aryl or heterocyclyl and
• R 8 represents hydrogen, cycloalkyl, heterocyclyl or lower alkyl optionally mono substituted by cycloalkyl, optionally substituted aryl, hydroxy, lower alkoxy, optionally substituted heteroaryl, heterocyclyl or hydroxy-loweralkoxy, or, when R 7 and R 8 are both attached to nitrogen, R 7 and R 8 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heterocycle optionally containing an additional heteroatom selected from N, S and O and optionally being substituted by lower alkyl, lower alkoxy or hydroxy-lower alkyl;
• n 0-3;
• R 2 is H
• R 3 represents hydrogen, -COR 4 , -CONR 4 R 5 , -CONHOR 6 , cyano, halogen, -CO 2 R 5 , -SO 2 NR 4 R 5 , -OR 4 , lower alkyl optionally substituted independently by cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclyl, hydroxy, -CONR R 5 or -CO 2 R 5 , or lower alkenyl optionally substituted independently by cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclyl, hydroxy, -CONR 4 R 5 or -CO 2 R 5 , wherein
• R 4 represents hydrogen, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclyl, or lower alkyl optionally mono substituted by cycloalkyl, optionally substituted aryl or heterocyclyl;
• R 5 represents hydrogen, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclyl or lower alkyl optionally substituted independently by -CONH 2 , cycloalkyl, optionally substituted aryl, optionally substituted aryloxy, hydroxy, lower alkoxy, optionally substituted heteroaryl, heterocyclyl, hydroxy-loweralkoxy or -NR'R" wherein R' is hydrogen or lower alkyl optionally substituted by optionally substituted aryl and R" is -COCH 3 , lower alkyl or optionally substituted aryl ;
• R 6 represents hydrogen or heterocyclyl
• R 4 and R 5 when R 4 and R 5 are both attached to nitrogen, R 4 and R 5 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heterocycle optionally containing an additional heteroatom selected from N, S and O and optionally being independently substituted at one or more carbon and/or N-atoms by lower alkyl, lower alkoxy or hydroxy-lower alkyl;
• the compounds of the present invention may posses one or more asymmetric carbon atoms.
• the invention extends to all such forms (enantiomers, diastereoisomers) and to mixtures thereof, including enantiomeric mixtures (racemates), diastereoisomeric mixtures and mixtures of both such mixtures.
• lower alkyl means a saturated straight- chain or branched-chain hydrocarbon containing from 1 to 7, preferably from 1 to 4, carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.butyl, tert.butyl, n-pentyl, n-hexyl, n-heptyl and the like.
• lower alkoxy means a lower alkyl group as defined earlier which is bonded via an oxygen atom, with examples of lower alkoxy groups being methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec.butoxy, tert-butoxy, n- pentoxy and the like.
• lower alkenyl means a lower alkyl group as defined earlier which contains one double bond of either E or Z stereochemistries, for example ethenyl, prop-2-enyl, but-2-enyl, 2-ethenyl-butyl and the like.
• cycloalkyl means a saturated cyclic hydrocarbon group of 3 to 8 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
• optionally substituted aryl means a phenyl or an optionally partly saturated naphthyl group which is unsubstituted or optionally substituted with one or more, preferably one or two, substituents selected from halogen, lower alkoxy, haloalkyl, hydroxy, -COOR' (wherein R' is H, lower alkyl), nitro, amino, sulfamoyl, phenyl or lower alkyl optionally mono substituted by lower alkoxy or hydroxy, particularly by halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitro, amino or sulfamoyl.
• partially saturated naphthyl means a naphthyl group, to which one or two H 2 molecules were added.
• An example of a partially saturated naphthyl group is 1,2,3,4-tetrahydro-l -naphthyl.
• aryloxy means a group R a -O-, wherein R a is optionally substituted aryl as defined before.
• optionally substituted heteroaryl means an aromatic group of 5- or 6 ring atoms containing one or more, preferably one, two or three, hetero atoms independently selected from N, S and O, the remaining ring atoms being C and which aromatic group is optionally benz-fused.
• the heteroaryl is optionally substituted independently at one or more, preferably one or two, ring atoms by halogen, lower alkyl optionally substituted by lower alkoxy or hydroxy, lower alkoxy, haloalkyl, hydroxy, -COOR' (wherein R' is H, lower alkyl), nitro, amino, sulfamoyl or optionally substituted aryl; particularly by halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitro, amino or sulfamoyl.
• heteroaryl groups are pyrrolyl, pyrazolyl, thienyl, furanyl, pyridyl, pyrimidinyl, quinolyl, indolyl, benzofuranyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl and , if benz-fused, indolyl, benzofuranyl, or benzimidazolyl.
• substituted heteroaryl groups are 5-methyl-3H-imidazol-4-yl, l-methyl-2-pyrrolyl, 3-methoxy- lH-pyrrol-2-yl, 3-phenyl- lH-pyrazol-4-yl, 3- (4-methoxyphenyl)- 1H- pyrazol-4-yl, 3-methyl-lH-pyrazol-4-yl, 5-(2-nitro-phenyl)-2H-pyrazol-3-yl, 2- ethoxycarbonyl-3-(2-ethoxycarbonyl-ethyl)-4-ethoxycarbonylmethyl-pyrrol-5-yl or 2-ethoxycarbonyl-3,4-dimethyl-pyrrol-5-yl and, if benz-fused, 5-methoxy-lH-indol-3-yl, 6-methyl-lH-indol-2-yl, 6-chloro- lH-benzimidazol-2-yl, 5-chloro- lH-
• heterocyclyl or “heterocycle” means, if not defined otherwise, a saturated, or partially unsaturated, cyclic group of 3- to 7, preferably 5- or 6, ring atoms in which one or more, preferably one, two or three, ring atoms are hetero atoms/groups selected from N, S, SO 2 and O, the remaining being C, which is linked via a carbon or nitrogen ring atom.
• partially unsaturated cyclic group means a cyclic group, from whose saturated form one or two H 2 molecules were removed.
• heterocyclyl groups are aziridinyl, pyrrolidinyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, piperidinyl, piperazinyl, morpholinyl or tetrahydro-l,l-dioxo-3-thienyl.
• halogen used alone or in combination as in “haloalkyl”, means fluorine, chlorine, bromine or iodine.
• haloalkyl means a lower alkyl group wherein one or more, preferably one or two, hydrogens are replaced by one or more halogen atoms, for example -CH 2 C1, -CF 3 , -CH 2 CC1 3 , -CH 2 CF 3 .
• hydroxy-lower alkyl means a lower alkyl group as defined earlier wherein a hydrogen atom is replaced by a hydroxy group. Examples of such groups are hydroxymethyl, 3-hydroxypropyl, 2-hydroxyethyl, 2-hydroxy-l,l-dimethyl- ethyl or 5-hydroxy-pentyl.
• hydroxy-lower alkoxy- means a lower alkoxy group as defined before wherein a hydrogen has been replaced by hydroxy.
• An example of such a group is 2-(2-hydroxy-ethoxy)ethyl.
• the compounds of formula I which are acidic form pharmaceutically acceptable salts with bases such as alkali metal hydroxides (e.g. sodium hydroxide and potassium hydroxide), alkaline earth metal hydroxides (e.g. calcium hydroxide and magnesium hydroxide), ammonium hydroxide and the like.
• bases such as alkali metal hydroxides (e.g. sodium hydroxide and potassium hydroxide), alkaline earth metal hydroxides (e.g. calcium hydroxide and magnesium hydroxide), ammonium hydroxide and the like.
• bases such as alkali metal hydroxides (e.g. sodium hydroxide and potassium hydroxide), alkaline earth metal hydroxides (e.g. calcium hydroxide and magnesium hydroxide), ammonium hydroxide and the like.
• alkali metal hydroxides e.g. sodium hydroxide and potassium hydroxide
• alkaline earth metal hydroxides e.g. calcium hydroxide and magnesium hydroxide
• ammonium hydroxide and the like e
• the monocyclic aromatic ring in R 1 is a 5- or 6-membered ring, containing one, two, three or four heteroatoms, especially a 5-membered ring contaiing one, two, three or four heteroatoms.
• the monocyclic ring is selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, thienyl or furanyl and, if benz-fused, from benzimidazolyl or indolyl.
• the monocyclic or benz-fused ring in R 1 is pyrrolyl, pyrazolyl, imidazolyl, and indolyl, in particular pyrrolyl and pyrazolyl.
• Particularly preferred monocyclic rings within R 1 are 1-H- imidazol-2-yl, lH-imidazol-4-yl, 2-pyrrolyl and lH-pyrazol-4-yl, and, if benz- fused, l-H-indol-3-yl or lH-indol-2-yl, preferably pyrrol- 2 -yl and lH-pyrazol-4- yl.
• the monocyclic or benz-fused ring is preferably unsubstituted or substituted independently at one or more, preferably one or two, positions with lower alkyl, lower alkoxy, optionally substituted aryl or (CH 2 ) n CO 2 R 8 wherein n and R 8 are as defined above.
• n is preferably 0-2 and R 8 is preferably lower alkyl, especially ethyl.
• the monocyclic or benz-fused ring in R 1 is substituted by lower alkyl, especially methyl; lower alkoxy, especially methoxy; optionally substituted aryl, especially phenyl, 2-nitrophenyl, or 4-methoxyphenyl; carbethoxy, carbethoxymethyl or carbethoxyethyl.
• R 1 groups are l-H-imidazol-2-yl, lH-imidazol-4-yl, 5- methyl-3H-imidazol-4-yl, l-H-indol-3-yl, 5-methoxy-lH-indol-3-yl, lH-indol-2- yl, 6-methyl-lH-indol-2-yl, 2-pyrrolyl, l-methyl-2-pyrrolyl, 3-methoxy-lH- pyrrol-2-yl, lH-pyrazol-4-yl, 3-phenyl-lH-pyrazol-4-yl, 3-(4-methoxyphenyl)- lH-pyrazol-4-yl, or 3-methyl-lH-pyrazol-4-yl, 5-(2-nitro-phenyl)-2H-pyrazol-3- yl, 2-ethoxycarbonyl-3-(2-ethoxycarbonyl-ethyl)-4-
• R 3 is hydrogen, lower alkyl optionally substituted by hydroxy, -COR 4 , -CONR 4 R 5 , -CONHOR 6 , cyano, -CO 2 R 5 , -SO 2 NR 4 R 5 or lower alkenyl optionally substituted by -CO 2 R 5 ; more preferably R 3 is hydrogen, -CONR R 5 , -CONHOR 6 , -CO 2 R 5 or cyano.
• R 4 is preferably hydrogen or lower alkyl, especially methyl, preferably hydrogen, and R 5 is as defined above, more preferably R 5 is hydrogen, cycloalkyl (e.g. cyclooctyl), optionally substituted aryl (e.g. phenyl, 1,2,3,4-tetrahydro-l- naphthyl), heterocyclyl (e.g. tetrahydro-l,l-dioxo-3-thienyl), lower alkyl (e.g.
• heteroaryl e.g. , furan-2-yl-rnethyl, 2- thiophen-2-yl-ethyl, 2-indol-3-yl-ethyl, pyridin-4-ylmethyl, 2-pyridin-2-yl-ethyl, pyridin-2-ylmethyl, lH-benzimidazol-2-ylmethyl, 6-chloro- lH-benzimidazol-2- ylmethyl, 2-(5-chloro- lH-benzimidazol-2-yl)-ethyl, 6-methoxy- lH-benzimidazol- 2-ylmethyl, 6-chloro-lH-benzimidazol-2-ylmethyl), heterocyclyl (e.g.
• the lower alkyl in R 5 is mono- or di-substituted, especially mono- substituted, by one of the above mentioned groups. If disubstituted, the lower alkyl is preferably disubstituted by optionally substituted aryl (e.g. 1,2-diphenyl-ethyl) or by optionally substituted aryl and hydroxy-lower alkyl (e.g. 2-hydroxy-l(R)- phenylethyl).
• aryl e.g. 1,2-diphenyl-ethyl
• hydroxy-lower alkyl e.g. 2-hydroxy-l(R)- phenylethyl
• R 6 is preferably hydrogen.
• R 4 is preferably lower alkyl, especially methyl.
• R 5 is preferably hydrogen or lower alkyl, especially methyl or tert-butyl. If R 3 is lower alkenyl optionally substituted by -CO 2 R 5 , R 5 is preferably lower alkyl, especially methyl or ethyl.
• R 3 is hydrogen, cyano or -CONH 2 .
• R 4 and R 5 together with the nitrogen atom to which they are attached represent a 5- or
• heterocycle is optionally independently substituted at one or two carbon and/or N-atoms.
• the heterocycle is preferably morpholino or pyrrolidinyl. Particular substituents are methyl or hydroxymethyl.
• An especially preferred heterocycle is morpholino and a preferred substituted heterocycle is 2(R)-(hydroxymethyl)-l-pyrrolidinyl.
• a preferred heterocyclyl substituent in R 6 is tetrahydro-pyran-2-yl.
• a further embodiment of the compounds of the present invention is wherein R 1 is l-H-pyrrol-2-yl and R 3 is hydrogen, cyano or -CONR 4 R 5 .
• Particularly preferred compounds of the invention are:
• the present invention relates to a process for the preparation of compounds of formula I.
• the compounds of formula I as described herein before and their pharmaceutically acceptable salts are manufactured by a process which comprises reacting a compound of the general formula
• R 1 is as above,
• the reaction between compounds II and III is preferably effected in the presence of a base such as piperidine in a lower alkanol such as 2-propanol at a temperature between 0°C and the reflux temperature of the solvent, preferably at about 75°C.
• a base such as piperidine
• a lower alkanol such as 2-propanol
• Starting materials of formula III are known compounds or analogues of known compounds that can be prepared in a similar manner to the known compounds.
• many compounds of formula III are commercially available, for example, from Sigma-Aldrich Company Ltd., Lancaster Synthesis Ltd. or Maybridge Chemical Company Ltd. (e.g. py ⁇ role-2-carboxaldehyde,
• starting materials of formula III may be prepared by adaptation of the methods in Vilsmeier et al., Chem. Ber., 60, 119, 1927, and Konvar et al., Tetrahedron Lett, 28, 955, 1987, for the introduction of a formyl group into appropriately substituted 5- or 6-membered monocyclic aromatic rings containing one or more hetero atoms independently selected from N, S and O.
• 3-substituted pyyrole-2-carboxaldehydes such as 3- methoxypyrrole-2-carboxaldehyde (used in Examples 13, 64, 65, 66 and 67), may also be prepared by photolytic ring- contraction of the corresponding 4-substituted pyridine-N-oxides as described in Campbell, S.E. et al., J. Chem. Soc. Perkin Trans. 1, 15, 2195-2202, 1997.
• Acidic compounds of formula I can be converted into pharmaceutically acceptable salts by treatment with bases and basic compounds of formula I can be converted into pharmaceutically acceptable salts by treatment with acids. Such treatments can be carried out in a conventional manner.
• a compound of formula (IV) is reacted with a nitrating mixture, preferably with trifluoroacetic anhydride/ ammonium nitrate in a halogenated aliphatic hydrocarbon, especially chloroform.
• a nitrating mixture preferably with trifluoroacetic anhydride/ ammonium nitrate in a halogenated aliphatic hydrocarbon, especially chloroform.
• the reaction is carried out at about 0°C to about 30°C.
• the next step comprises reduction of the compound of formula (V) to give the amine of formula (VI).
• This reduction is carried out using reduced iron powder, iron sulfate heptahydrate in aqueous dioxan solvent at about 90°C to about 115°C, preferably at about 110°C.
• the cyclisation is carried out in a solvent which is inert under the reaction conditions such as tetrahydrofuran or, preferably, a halogenated aliphatic hydrocarbon, especially dichloromethane, at about -78°C to about 30°C, preferably at about 0°C to about room temperature.
• a solvent which is inert under the reaction conditions such as tetrahydrofuran or, preferably, a halogenated aliphatic hydrocarbon, especially dichloromethane, at about -78°C to about 30°C, preferably at about 0°C to about room temperature.
• the next step comprises a reaction of a compound of formula (VII) with an aldehyde of formula (III) to give a compound of formula (VIII).
• This condensation is carried out with an organic base, preferably piperidine, in a lower alkanol such as 2-propanol at a temperature between 50°C and 100°C.
• a compound of formula (IX) is reacted with ethyl chloroacetate to give a compound of formula (X).
• This reaction is conveniently carried out under inert atmosphere in a solvent which is inert under the reaction conditions, preferably a cyclic ether, especially tetrahydrofuran, at about -78°C to about 30°C, preferably at about -50°C to about room temperature.
• the next step comprises reduction of the compound of formula (X) to give the amine of formula (XI).
• This reduction is carried out using reduced iron powder and iron sulfate heptahydrate in aqueous dioxan solvent at about 90°C to about 115°C, preferably at about 110°C.
• the cyclisation is carried out in a solvent which is inert under the conditions of the reaction such as tetrahydrofuran or, preferably, a halogenated aliphatic hydrocarbon, especially dichloromethane, at about -78°C to about 30°C, preferably at about 0°C to about room temperature.
• a solvent which is inert under the conditions of the reaction such as tetrahydrofuran or, preferably, a halogenated aliphatic hydrocarbon, especially dichloromethane, at about -78°C to about 30°C, preferably at about 0°C to about room temperature.
• the next step comprises a reaction of a compound of formula (XII) with an aldehyde of formula (III) to give a compound of formula (XIII).
• This condensation is carried out with an organic base, preferably piperidine in a lower alkanol such as 2-propanol at a temperature between 50°C and 100°C.
• Starting materials of formula (IX) are known compounds or analogues of known compounds that can be prepared in a similar manner to the known compounds.
• compounds of formula (IX) are commercially available, for example, from Sigma- Aldrich Company Ltd., Lancaster Synthesis Ltd., or Maybridge Chemical Company Ltd. (e.g. 5-nitrothiophene carboxamide, used in
• Example 19 Maybridge catalogue number RF 01604), or prepared by adaptation of the methods provided in Crivello et al., JOC, 1981, 46(15), 3056 for the nitration of optionally substituted thiophene rings.
• R 3 represents CO 2 R 5 and R 5 represents hydrogen) the carboxylic acid must be in protected form. Suitable protection is , for example, as an ester such as tert-butyl ester which may subsequently be removed by reaction with trifluoroacetic acid.
• Another aspect of the present invention are compounds of the general formula
• the thienopyrrolidinones provided by the present invention are useful as inhibitors of cellular production of tumour necrosis factor (TNF- ⁇ ) and as antiproliferative agents. These activities can be demonstrated by using procedures as described hereinafter.
• the following assay may be used to demonstrate the ability of the compounds of the invention to inhibit LPS induced TNF- ⁇ production in THP-1 cells.
• the assay uses a modification of the methods described in Blifield et al., Transplantation, 51:498-503 (1991).
• THP-1 cells were suspended in serum free culture medium LGM-3 (Clonetics, Bio Whittaker, UK, Cat. No. CC-3211), at a concentration of 5 x 10 5 cells/ml and then plated in 96 well-plates (0.2 ml aliquots in each well). Test compounds were dissolved in DMSO and then diluted with the culture medium such that the final DMSO concentration was 1%. Twenty five ⁇ l aliquots of test solution or only medium with DMSO (control) were added to each well giving a final DMSO concentration of 0.1%. The cells were incubated for 30 min. at 37°C.
• LPS (Sigma Chemical Company, UK) was added to the wells at a final concentration of 2 ⁇ g/ml, and cells were incubated for ah additional 4 hours. At the end of the incubation period, culture supernatants were collected and the amount of TNF- ⁇ present was determined using a commercial TNF- ⁇ ELISA assay as described below.
• the assay was carried out according to the manufacturer's instructions with the following modifications. Assay plates were centrifuged at 200 g and a 200 ⁇ l sample added to each well. TNF- ⁇ standard was made up and diluted in LGM-3 culture medium. Samples in the ELISA plate were then incubated overnight at 4°C instead of 2 hours at 37°C. TNF- ⁇ production for each condition was calculated and expressed as a percentage of DMSO control to enable IC 50 calculation.
• TNF tumour necrosis factor
• LGM-3 lymphocyte growth medium 3
• the anti-proliferative activity of the compounds of the invention maybe determined, for example, by use of the following assays:
• the estrogen receptor negative epithelial breast carcinoma line (MDA-MB- 435) can be purchased from American Type Cell Culture Collection (ATCC;
• test compounds are assayed in duplicate.
• DMSO is added to a row of "control cells” such that the final concentration of DMSO in each well is 0.3%.
• Wells to which no cells are added serve as the "blank”.
• Wells to which no inhibitor is added serve as "no inhibitor control”. The plates are returned to the incubator, and 5 days post addition of test compound, are analysed as described below.
• MTT thiazolyl blue
• MTT-containing medium 100 ⁇ l of 100% ethanol is added to each well to dissolve the resulting formazan metabolite.
• plates are shaken for 15 minutes at room temperature. Absorbencies are read in a microtiter plate reader (Molecular Dynamics) at a wavelength of 570 nm with a 650 nm reference. Percent inhibition is calculated by subtracting the absorbance of the blank (no cell) wells from all wells, then subtracting the division of the average of the controls from 1.00.
• Inhibitory concentrations are determined from the linear regression of a plot of the logarithm of the concentration versus the percent inhibition.
• the colon carcinoma line SW480 can also be obtained from the ATCC (ATCC No. CCL-228) and tested according to the same protocol provided above with the following modification: cell line SW480 is plated at 1000 cells per well and analysed at 4 days post addition of test compound.
• the compounds of formula (I) are suitable for use as therapeutically active compounds, particularly for use in the treatment of neuro-degenerative diseases, cardiovascular diseases, cancer or as anti-inflammatory agents.
• the present invention relates to a medicament containing a compound of formula (I) and a therapeutically inert carrier material, especially a medicament for the control or prevention of neuro-degenerative diseases, cardiovascular diseases, cancer or inflammatory diseases.
• a further aspect is the use of a compound of the present invention for the manufacture of a medicament for the control or prevention of neuro-degenerative diseases, cardiovascular diseases, cancer or inflammatory diseases.
• the compounds are useful in the treatment of inflammatory diseases, especially in connection with degenerative joint diseases such as rheumatoid arthritis and ostheoarthritis.
• TNF- ⁇ tumour necrosis factor
• RA rheumatoid arthritis
• TNF- ⁇ appears to play a pivotal role ( Fox, David A., Arch. Intern. Med., Vol 160(4), 437-444, 2000).
• the specific causative agent of the pathological process of osteoarthritis (OA) has not been identified, but episodic inflammation at the clinical stage is well documented and believed to be involved in disease progression.
• TNF- ⁇ is a predominant proinflammatory cytokine synthesised during the OA process (Martel-Pelletier, J. et al., Frontiers in Bioscience, Vol 4, d694-703, 1999; Blackburn, Warren D. Jr., American Journal of
• the compounds of the invention are also inhibitors of cellular proliferation. Cancer is characterised by dis-regulated cellular proliferation; therefore compounds of the invention are useful in the treatment of cancer.
• the compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments, for example in the form of pharmaceutical preparations.
• the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, they can also be administered rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
• the compounds of formula (I) and their pharmaceutically acceptable salts can be formulated with therapeutically inert, inorganic or organic carriers.
• Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
• Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi- solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, generally required in the case of soft gelatine capsules.
• Suitable carriers for the manufacture of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose and the like.
• Suitable carriers for the manufacture of injection solutions are, for example, water, alcohols, polyols, glycerine, vegetable oils and the like. Natural and hardened oils, waxes, fats, semi-liquid polyols and the like are suitable carriers for the manufacture of suppositories.
• the pharmaceutical preparations can also contain preservatives, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for adjustment of the osmotic pressure buffers, coating agents or antioxidants.
• Medicaments containing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically acceptable carrier as well as a process for the manufacture of such medicaments are also objects of the present invention.
• This process comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof with a therapeutically inert carrier material and bringing the mixture into a galenical administration form.
• the compounds of formula (I) and the pharmaceutically acceptable salts thereof can be used in the control or prevention of illnesses, especially in the control or prevention of inflammatory diseases such as degenerative joint diseases, especially rheumatoid arthritis; in the treatment of cardiovascular disorders; in the treatment of cancer such as invasive tumours, or the treatment of neuro-degenerative diseases.
• the dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case. In general, in the case of administration to adults, a daily dosage from about 0.1 mg/kg to about 50 mg/kg, preferably from about 0.5 mg/kg to about 5 mg/kg, should be appropriate, although the upper limit may be exceeded when this is found to expedient.
• the daily dosage can be administered as a single dosage or in divided dosages.
• 4,6-Dihydrothieno [2,3-b] pyrrol-5-one (30 mg, 0.22 mmol) was dissolved in a solution of 1% piperidine in 2-propanol (2 ml). Pyrrole-2-carboxaldehyde (40 mg, 0.43 mmol) was added in one portion and the mixture heated at 75°C for
• the starting material was prepared as follows:
• the starting material was prepared as follows:
• Example 20 The procedure outlined in Method C was used for the synthesis of the starting material used in Example 20 (5-nitrothiophene-2-carbonitrile) which is an item of commerce.
• the starting materials used in Examples 21 and 22 can be prepared from the commercially available 5-nitrofhiophene-2-carboxylic acid in a manner known per se. Method C was then used for preparation of the respective starting materials.
• Example 20 The procedure outlined in Method C was used for the synthesis of the starting material used in Example 20 (5-nitrothiophene-2-carbonitrile) which is an item of commerce.
• the starting materials used in Examples 21 and 22 can be prepared from the commercially available 5-nitrofhiophene-2-carboxylic acid in a manner known per se. Method C was then used for preparation of the respective starting materials.
• Example 20 The procedure outlined in Method C was used for the synthesis of the starting material used in Example 20 (5-nitrothiophene-2-carbonitrile) which is an item of commerce.
• the starting materials used in Examples 21 and 22
• tert-Butyl 5,6-dihydro-5-oxo-4H-thieno[2,3-b]pyrrole-2-carboxylate 915 mg, 3.8 mmol
• 2-propanol 10 ml
• 3-Methoxypyrrole-2-carboxaldehyde (3.8 mmol, 480 mg) was added in one portion and the mixture heated at 75°C for 1 hour.
• tert-Butyl 5,6-Dihydro-5-oxo-4H-thieno[2,3-b]pyrrole-2-carboxylate 300 mg, 1 mmol was dissolved in toluene (25 ml).
• Diisobutylaluminium hydride 1.5 mmol, 1.5 ml of a 1 M solution in toluene was added dropwise and the reaction mixture stirred at room temperature for 2 hours.
• Methanol (1ml) was added and then diluted with ethyl acetate and washed with 2M hydrochloric acid, saturated sodium bicarbonate and water.
• tert-Butyl 5,6-Dihydro-5-oxo-4H-thieno[2,3-b]pyrrole-2-carboxylate 300 mg, 1 mmol was dissolved in dichloromethane (40 ml).
• Diisobutylaluminium hydride (2 mmol, 2 ml of a 1 M solution in dichloromethane) was added dropwise and the reaction mixture stirred at room temperature for 2 hours then diluted with ethyl acetate and washed with saturated sodium bicarbonate, saturated brine solution and water.
• the starting material was prepared as follows:
• reaction mixture was stirred at - 30°C for 30 minutes then quenched with 2M HC1 (50 ml), diluted with ethyl acetate, washed with water, dried over magnesium sulfate and evaporated to dryness. The residue was chromatographed on silica gel using hexane/diethyl ether
• the starting material was prepared as follows:
• Tablets containing the following ingredients may be produced in a conventional manner:
• Capsules containing the following ingredients may be produced in a conventional manner:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Cardiology (AREA)
• Hospice & Palliative Care (AREA)
• Heart & Thoracic Surgery (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9895032

Family Applications (1)

Country Status (16)

Cited By (2)

Families Citing this family (3)

Family Cites Families (12)

• 2000
  • 2000-07-04 GB GBGB0016454.1A patent/GB0016454D0/en not_active Ceased
• 2001
  • 2001-06-26 US US09/891,588 patent/US6528653B2/en not_active Expired - Fee Related
  • 2001-06-28 AT AT01967106T patent/ATE284887T1/de not_active IP Right Cessation
  • 2001-06-28 KR KR10-2003-7000084A patent/KR100519831B1/ko not_active Expired - Fee Related
  • 2001-06-28 ES ES01967106T patent/ES2233677T3/es not_active Expired - Lifetime
  • 2001-06-28 EP EP01967106A patent/EP1301517B1/en not_active Expired - Lifetime
  • 2001-06-28 DE DE60107852T patent/DE60107852T2/de not_active Expired - Fee Related
  • 2001-06-28 JP JP2002507819A patent/JP3878128B2/ja not_active Expired - Fee Related
  • 2001-06-28 WO PCT/EP2001/007423 patent/WO2002002567A1/en not_active Ceased
  • 2001-06-28 AU AU2001287568A patent/AU2001287568B2/en not_active Ceased
  • 2001-06-28 MX MXPA02012595A patent/MXPA02012595A/es active IP Right Grant
  • 2001-06-28 PT PT01967106T patent/PT1301517E/pt unknown
  • 2001-06-28 AU AU8756801A patent/AU8756801A/xx active Pending
  • 2001-06-28 CA CA002414705A patent/CA2414705A1/en not_active Abandoned
  • 2001-06-28 BR BR0112147-2A patent/BR0112147A/pt not_active IP Right Cessation
  • 2001-06-28 CN CNB01812349XA patent/CN1186346C/zh not_active Expired - Fee Related
  • 2001-07-03 AR ARP010103167A patent/AR030241A1/es not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events